Annual report [Section 13 and 15(d), not S-K Item 405]

Accounts Payable and Accrued Expenses (Tables)

v3.26.1
Accounts Payable and Accrued Expenses (Tables)
12 Months Ended
Dec. 31, 2025
Accounts Payable and Accrued Expenses  
Schedule of Accounts Payable and Accrued Expenses

​

​

​

​

​

​

​

​

​

December 31,

($ in thousands)

​

2025

  ​ ​ ​

2024

Accounts payable

​

$

3,510

​

$

7,464

Accrued research and development

​

​

250

​

​

330

Accrued compensation

​

​

24

​

​

93

Other(1)

​

​

1,627

​

​

1,599

Total accounts payable and accrued expenses

​

$

5,411

​

$

9,486

​

​

(1) Other includes approximately $1.3 million of accrued consideration for the uBriGene Asset Purchase Agreement, see Note 4.